Breast Cancer

Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.

Not only did the Navya-Patient Preference Tool help patients with decision-making, but groups who used the tool were more likely to receive their preferred form of surgery.

The manager of patient support services at St. Luke’s Cancer Center discusses the significance of Reaching Out for Healthy Women and how female patients can receive support from this initiative.

Lack of awareness, cultural beliefs, and physician preferences may influence whether minority patients receive palliative care during metastatic breast cancer treatment.

Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.

Ryan Haumschild, PharmD, MS, MBA, leads drives a conversation surrounding the impact of CDK4/6 inhibitors in treatment of metastatic breast cancer.

A panel of medical experts begin a discussion surrounding key updates in treatment and management of HR+/HER2- metastatic breast cancer.

The study authors suggest that after initiating alpelisib, patients should be proactive by improving glycemic status to reduce the risk of developing hyperglycemia.

Dr Moore provides a detailed summary of the scope and findings from the TROPiCS-02 study.

Heather Moore, CPP, PharmD, highlights key contributions from pharmacists in breast cancer treatment and identifies current unmet needs in the treatment landscape.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

AACR has urged Congress to provide billions more in funding for cancer research, prevention efforts, and expedited review of cancer-related medical products.

Researchers found an increased risk of breast cancer in women who had higher particulate matter levels near their home.

The CDK12/13 inhibitor will be tested for efficacy and safety in patients with advanced solid tumors, such as breast, ovarian, and Ewing Sarcoma.

Precision medicine in pharmacy has the potential to revolutionize patient care by optimizing drug selection, dosing, and monitoring.

Investigators must find a different combination or treatment regimen using a dual blockade of the PARP and PI3K/AKT/mTOR pathway.

African ancestry was associated with higher odds of estrogen receptor-negative and triple-negative breast cancer; however, social environments were strongly associated with the survival of Black individuals with breast cancer.

Patients with cancer and survivors of cancer that had engaged in administrative tasks to effectively estimate costs or pay for care was associated with an 18% increase in cost-related treatment delays or treatment nonadherence.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

Unexpectedly, a study found that more than 70% of cancer survivors were current drinkers, indicating the need for intervention and strategies to reduce harmful drinking habits.

Microgravity provides researchers with a unique environment for studying how cells behave differently than they do on Earth.

After carboplatin joined the growing list of drug shortages, staff pharmacists acted to minimize the impact on patients.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

The results of a study showed that the median progression-free survival was shorter for patients with advanced breast cancer who use proton pump inhibitors with palbociclib.

Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.

Building on promising prior research, ERβ was found to prevent aggressive forms of breast cancer from metastasizing.

Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.

There are currently no effective treatments for CIPN prevention.